Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy

PURPOSE: New therapies are needed to treat immune checkpoint inhibitor-resistant non- small cell lung cancer (NSCLC) and identify biomarkers to personalize treatment. Epigenetic therapies, including histone deacetylase inhibitors, may synergize with programmed cell death-1 (PD-1) blockade to overcom...

全面介紹

Na minha lista:
書目詳細資料
發表在:Clin Cancer Res
Main Authors: Hellmann, Matthew D., Jänne, Pasi A., Opyrchal, Mateusz, Hafez, Navid, Raez, Luis E., Gabrilovich, Dmitry, Wang, Fang, Trepel, Jane B., Lee, Min-Jung, Yuno, Akira, Lee, Sunmin, Brouwer, Susan, Sankoh, Serap, Wang, Lei, Tamang, David, Schmidt, Emmett, Meyers, Michael L., Ramalingam, Suresh S., Shum, Elaine, Ordentlich, Peter
格式: Artigo
語言:Inglês
出版: 2020
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7887114/
https://ncbi.nlm.nih.gov/pubmed/33203644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3305
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍